Floatz logo

EFTRENONACOG ALFA

Severe Hemophilia B

Bioverativ Therapeutics Inc.protein_peptidePhase 3Dormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Severe Hemophilia B cohort.

Asset / SponsorPhaseRating
Rfix
Bioverativ Therapeutics Inc.
Phase 3BB

Same molecule, other indications

EFTRENONACOG ALFA is also rated in:

hemophilia BDormant
BB
Indicative ·
64 / 100
View asset →
inherited blood coagulation disorderDormant
CC
Indicative ·
47 / 100
View asset →
hemophilia BDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →